| 词条 | Bimagrumab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = u | target = ACVR2B | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1356922-05-8 | ATC_prefix = none | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = N15SW1DIV8 | PubChem = | DrugBank = | ChemSpiderID = none | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D10620 | C= 6306 | H= 9732 | N= 1684 | O= 1990 | S= 46 | molecular_weight = 142.4 kDa | synonyms = BYM338 }}Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration.[1] Bimagrumab is currently entering Phase II development, with some research indicating clinical effects.[2] In 2016, Novartis intends to apply for FDA approval to treat sIBM patients with Bimagrumab BYM338.[3] April 2016 Novartis said that its “breakthrough” drug bimagrumab (BYM338) failed a Phase IIb/III study for sporadic inclusion body myositis.[4] References1. ^{{cite web|title=Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)|url=http://www.novartis.com/newsroom/media-releases/en/2013/1723765.shtml|accessdate=20 August 2013}} {{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{Monoclonals for immune system}}{{monoclonal-antibody-stub}}2. ^{{cite journal | pmid = 25381300 | doi=10.1212/WNL.0000000000001070 | volume=83 | title=Treatment of sporadic inclusion body myositis with bimagrumab | pmc=4277670 | journal=Neurology | pages=2239–46 | last1 = Amato | first1 = AA | last2 = Sivakumar | first2 = K | last3 = Goyal | first3 = N | last4 = David | first4 = WS | last5 = Salajegheh | first5 = M | last6 = Praestgaard | first6 = J | last7 = Lach-Trifilieff | first7 = E | last8 = Trendelenburg | first8 = AU | last9 = Laurent | first9 = D | last10 = Glass | first10 = DJ | last11 = Roubenoff | first11 = R | last12 = Tseng | first12 = BS | last13 = Greenberg | first13 = SA}} 3. ^Novartis: Planned filings 2015 to >=2019. Retrieved 27 May 2015. 4. ^Novartis’ ‘breakthrough’ muscle drug bimagrumab flunks a late-stage trial 4 : Monoclonal antibodies|Novartis|Novartis brands|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。